Simplify Logo

Full-Time

Director – Quality Assurance

Posted on 7/15/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Hardware
Biotechnology
Healthcare

Compensation Overview

$200k - $230kAnnually

+ Performance Bonus + Equity

Expert

Remote in USA

Category
QA & Testing
Quality Assurance
Required Skills
Quality Assurance (QA)
Requirements
  • Bachelor's degree in a scientific discipline or equivalent experience
  • Minimum of 10 years pharmaceutical industry experience in Quality Assurance, as well as experience in both clinical development and commercial manufacturing
  • Thorough knowledge of applicable GXP regulations (e.g., CFRs and ICH)
  • Ability to build relationships and work collaboratively with a variety of individuals within the department, company, and external vendors
  • Strong team player with the ability to effectively communicate sound quality advice cross-functionally based on experience, regulations, and business needs
  • Travel – varies at 10-25% based on needs
Responsibilities
  • Assist in the design, preparation, and execution of inspection readiness activities
  • Participate in the coordination and execution of the internal audit program
  • Track and Prepare GXP internal and external metric reports periodically
  • Manage mock and live clinical recovery or drug product recall efforts
  • Support the planning, design, and implementation of commercial readiness initiatives
  • Contribute to the management, maintenance, and evaluation of QED’s Quality Management Systems and processes
  • Ensure GXP compliance with regulatory requirements and internal procedures
  • Aid in the continuous supply of drug products for sponsored clinical trials and business partners
  • Author and implement QA GXP standard operating procedures (SOPs)
  • Other duties as assigned or required

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Unlike many competitors, BridgeBio emphasizes independent thinking and transparency, enabling rapid, data-driven decision-making. The company's goal is to create significant therapeutic advancements by targeting diseases at their genetic source, ultimately bringing effective treatments to market more quickly.

Company Stage

IPO

Total Funding

$6.8B

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

53%

2 year growth

56%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.
INACTIVE